T14/NBP-14 Technology

About Neuro Bio

Neuro Bio is a private, preclinical-stage biotech pioneering a disruptive hypothesis for Alzheimer's disease (AD) that challenges the dominant amyloid dogma. The company's core discovery is the T14 peptide, which it posits triggers an aberrant, developmental-like process in specific vulnerable neurons, driving neurodegeneration upstream of amyloid plaque formation. This mechanism informs a dual strategy: a diagnostic pipeline for early detection of T14 in nasal secretions and saliva, and a therapeutic pipeline led by NBP-14, an antagonist of T14. The company is also exploring applications of its platform in oncology, dermatology, and diabetic retinopathy, indicating a broader platform potential.

Therapeutic Areas